HIMS · NYSE · Medical - Care Facilities

Hims & Hers Health (HIMS)

Connects personalized treatment plans with telehealth consultations and pharmacy fulfillment.

$29.22
vs last close−1.21 (−3.98%)

Hims & Hers turns private health concerns into recurring online care and delivered treatments. Weight management is now the largest engine, while older sexual-health, hair-care and skin-care subscriptions still make up most of the rest. The company is pushing overseas and into testing, hormones and future medicines, but the shift toward branded drugs brings lower margins and heavier regulatory dependence.

Item facts: FY2025 · year ended Dec 31, 2025, from filings, earnings calls and company pages.

Judgment weights, not filed revenue

Weight management~34%Sexual health~23%Hair care~18%Skin care~13%International care~8%Other care & testing~4%

The band summarizes business focus and direction. ~ marks estimates.

8 in detail · 6 more below

  • Weight Loss

    · Product lineRamping

    Weight-loss care is the biggest specialty, with fiscal 2025 sales of at least $725 million. The March 2026 move from broadly advertised custom-made weight drugs toward branded medicines raises drug costs and regulatory dependence.

    Competes with Ro Body Program (Ro) · WeightWatchers Clinic (WeightWatchers)

    In plain English

    A subscriber answers health questions, meets a provider online and, if eligible, gets ongoing support plus weight-loss medicine. Hims offers pills and branded appetite-regulating medicines such as Wegovy, Ozempic and Zepbound; custom-made versions are now restricted to cases where a clinician says they are necessary.

    This is a two-part checkout: the customer pays $149 a month for membership after the first month, then pays separately for medicine. Revenue continues while the customer stays enrolled and receives treatment, but more branded prescriptions send a larger part of each payment to drug makers.

  • Sexual Health

    · Product line

    A mature subscription built around erectile-dysfunction pills and personalized combinations. Nearly half a million subscribers used daily solutions at fiscal 2025 year-end; the watchpoint is whether daily plans offset weaker one-off pill sales.

    Competes with BlueChew erectile-dysfunction treatments (BlueChew) · Rex MD ED treatments (Rex MD)

    In plain English

    For many customers, this replaces an awkward office visit with a private online questionnaire, a medical review and a discreet parcel. The treatments include sildenafil or tadalafil, alone or combined with support for testosterone or climax control, taken either when needed or every day.

    Customers commonly pay about $22 to $39 a month and keep paying as refills arrive. Hims is nudging the category from occasional orders toward daily routines: those plans create steadier sales and tend to keep subscribers longer, though the older order-when-needed business has been weakening.

  • Hair Loss

    · Product line

    Long-running hair-loss subscriptions pair finasteride or minoxidil with regular delivery. Sales are not disclosed, but this mature line's job is to keep producing repeat cash while newer specialties absorb investment.

    Competes with Keeps plans (Thirty Madison) · Happy Head formulas (Happy Head)

    In plain English

    The unglamorous part that helps pay for everything newer. Hims and Hers sell single medicines and personalized combinations as pills, topical treatments and nonprescription products, generally costing about $13 to $35 a month.

    Hair loss usually needs continued treatment rather than a one-time fix, so the business behaves like a replenishment shelf: customers complete an online intake, a provider approves prescription care when needed, and a mail pharmacy sends refills. That regular rhythm supports subscriptions, although cheap widely available medicines make personalization and a smooth service important reasons to stay.

  • Dermatology

    · Product line

    Personalized acne and anti-aging prescriptions sit beside cleansers and moisturizers. Some acne creams combine as many as five ingredients; growth depends on making tailored formulas worth returning for when common ingredients are easy to find elsewhere.

    Competes with Custom Formula (Curology) · The Acne Cream (Musely)

    In plain English

    Think of a made-to-order skin-care counter. A customer shares symptoms and goals online, a provider chooses a prescription when appropriate, and Hims or Hers sends a cream or other treatment to the door. The range covers acne, signs of aging, cleansers and moisturizers.

    The money comes from repeat deliveries, with Hers' acne cream starting around $29 a month. Its point of difference is the recipe: one cream can contain as many as five ingredients chosen for the customer. Because many of those ingredients are common, keeping people subscribed matters as much as winning the first order.

  • International Platforms

    · PlatformRamping

    These are the same kinds of treatments sold outside the United States, not a separate kind of care. Overseas revenue reached 17.4% in the second quarter of fiscal 2026; integrating acquired platforms under different local rules is what matters next.

    Competes with Numan Weight Loss Programme (Numan) · Manual Weight Loss (Manual)

    In plain English

    Three acquired operations carry the model beyond the United States: ZAVA provides online care in Europe, Medici became Hims & Hers Canada and Livewell, and Eucalyptus brings the Juniper and Pilot services. They are local front doors to the same basic exchange—customers pay for remote care and delivered treatments.

    The overseas business earns as local subscribers order and renew, while ZAVA also handles medical requests for partner storefronts. Eucalyptus made the expansion much larger as soon as it joined. Different clinical and privacy rules in each country make this less like copying a website and more like fitting a new key for every door.

  • Low Testosterone

    · Product lineRamping

    Launched in the second half of fiscal 2025, this became the fastest-growing specialty outside weight management. Management expects it to approach a $100 million yearly sales pace; testing and hormone-care rules gate that growth.

    Competes with Hone TRT (Hone Health) · Rex MD Testosterone (Rex MD)

    In plain English

    Here the sale begins with proof. A man completes lab work, a provider reviews the result, and only someone found eligible moves into treatment. The current main offer is a prescription drug called enclomiphene, priced on a prepaid plan equal to $99 a month.

    Hims earns as approved customers continue treatment and repeat the required monitoring. The company plans to add injectable and oral choices, which could serve more preferences but also makes careful testing and medical oversight more important. Labs and drug makers get paid along the way; Hims connects those steps into one service.

  • Labs

    · ServiceRamping

    A paid health check covering more than 130 body measurements, followed by interpretation and an action plan. The bigger opportunity is not the test alone, but whether results lead eligible customers into other Hims care.

    Competes with Function membership (Function Health) · Superpower membership (Superpower)

    In plain English

    Instead of waiting for a symptom, customers can order a broad health check through Hims. A provider orders the work, Quest draws the sample at one of its locations, and Hims explains the results and suggests next steps; testing partner GRAIL supplies an optional Galleri screening test.

    Customers pay for the testing and guidance. The service can also reveal that someone may qualify for another Hims treatment, but that later purchase belongs to the other specialty. Hims bought YourBio to work toward small at-home blood samples, which could remove the trip to a collection site if it reaches scale.

  • Peptide Therapeutics

    · ProductPre-revenue

    Nothing is being sold yet. Hims may pay an unnamed manufacturing partner up to $30 million over twelve months as work clears agreed progress steps; any product launch still depends on regulators.

    Competes with Hone peptide program (Hone Health) · PT-141 therapy (Lifeforce)

    In plain English

    This is a planned line of prescription treatments known as peptides, not a current business. Hims is building the ability to make their ingredients and finished doses. Several are targeted to launch first, while one candidate called BPC-157 can move only if regulators permit it.

    If launched, Hims would connect manufacturing, provider approval and pharmacy delivery, earning money when eligible patients receive treatment. For now the flow runs the other way: the company is investing in production and may owe its technology partner as development steps are completed. Management attention gives the project strategic weight, but there are no customers or sales to count yet.

  • Weight Loss· Product lineRampingWeight-loss care is the biggest specialty, with fiscal 2025 sales of at least $725 million. The March 2026 move from broadly advertised custom-made weight drugs toward branded medicines raises drug costs and regulatory dependence.

    Weight-loss care is the biggest specialty, with fiscal 2025 sales of at least $725 million. The March 2026 move from broadly advertised custom-made weight drugs toward branded medicines raises drug costs and regulatory dependence.

    In plain English

    A subscriber answers health questions, meets a provider online and, if eligible, gets ongoing support plus weight-loss medicine. Hims offers pills and branded appetite-regulating medicines such as Wegovy, Ozempic and Zepbound; custom-made versions are now restricted to cases where a clinician says they are necessary.

    This is a two-part checkout: the customer pays $149 a month for membership after the first month, then pays separately for medicine. Revenue continues while the customer stays enrolled and receives treatment, but more branded prescriptions send a larger part of each payment to drug makers.

    Competes with Ro Body Program (Ro) · WeightWatchers Clinic (WeightWatchers)

  • Sexual Health· Product lineA mature subscription built around erectile-dysfunction pills and personalized combinations. Nearly half a million subscribers used daily solutions at fiscal 2025 year-end; the watchpoint is whether daily plans offset weaker one-off pill sales.

    A mature subscription built around erectile-dysfunction pills and personalized combinations. Nearly half a million subscribers used daily solutions at fiscal 2025 year-end; the watchpoint is whether daily plans offset weaker one-off pill sales.

    In plain English

    For many customers, this replaces an awkward office visit with a private online questionnaire, a medical review and a discreet parcel. The treatments include sildenafil or tadalafil, alone or combined with support for testosterone or climax control, taken either when needed or every day.

    Customers commonly pay about $22 to $39 a month and keep paying as refills arrive. Hims is nudging the category from occasional orders toward daily routines: those plans create steadier sales and tend to keep subscribers longer, though the older order-when-needed business has been weakening.

    Competes with BlueChew erectile-dysfunction treatments (BlueChew) · Rex MD ED treatments (Rex MD)

  • Hair Loss· Product lineLong-running hair-loss subscriptions pair finasteride or minoxidil with regular delivery. Sales are not disclosed, but this mature line's job is to keep producing repeat cash while newer specialties absorb investment.

    Long-running hair-loss subscriptions pair finasteride or minoxidil with regular delivery. Sales are not disclosed, but this mature line's job is to keep producing repeat cash while newer specialties absorb investment.

    In plain English

    The unglamorous part that helps pay for everything newer. Hims and Hers sell single medicines and personalized combinations as pills, topical treatments and nonprescription products, generally costing about $13 to $35 a month.

    Hair loss usually needs continued treatment rather than a one-time fix, so the business behaves like a replenishment shelf: customers complete an online intake, a provider approves prescription care when needed, and a mail pharmacy sends refills. That regular rhythm supports subscriptions, although cheap widely available medicines make personalization and a smooth service important reasons to stay.

    Competes with Keeps plans (Thirty Madison) · Happy Head formulas (Happy Head)

  • Dermatology· Product linePersonalized acne and anti-aging prescriptions sit beside cleansers and moisturizers. Some acne creams combine as many as five ingredients; growth depends on making tailored formulas worth returning for when common ingredients are easy to find elsewhere.

    Personalized acne and anti-aging prescriptions sit beside cleansers and moisturizers. Some acne creams combine as many as five ingredients; growth depends on making tailored formulas worth returning for when common ingredients are easy to find elsewhere.

    In plain English

    Think of a made-to-order skin-care counter. A customer shares symptoms and goals online, a provider chooses a prescription when appropriate, and Hims or Hers sends a cream or other treatment to the door. The range covers acne, signs of aging, cleansers and moisturizers.

    The money comes from repeat deliveries, with Hers' acne cream starting around $29 a month. Its point of difference is the recipe: one cream can contain as many as five ingredients chosen for the customer. Because many of those ingredients are common, keeping people subscribed matters as much as winning the first order.

    Competes with Custom Formula (Curology) · The Acne Cream (Musely)

  • International Platforms· PlatformRampingThese are the same kinds of treatments sold outside the United States, not a separate kind of care. Overseas revenue reached 17.4% in the second quarter of fiscal 2026; integrating acquired platforms under different local rules is what matters next.

    These are the same kinds of treatments sold outside the United States, not a separate kind of care. Overseas revenue reached 17.4% in the second quarter of fiscal 2026; integrating acquired platforms under different local rules is what matters next.

    In plain English

    Three acquired operations carry the model beyond the United States: ZAVA provides online care in Europe, Medici became Hims & Hers Canada and Livewell, and Eucalyptus brings the Juniper and Pilot services. They are local front doors to the same basic exchange—customers pay for remote care and delivered treatments.

    The overseas business earns as local subscribers order and renew, while ZAVA also handles medical requests for partner storefronts. Eucalyptus made the expansion much larger as soon as it joined. Different clinical and privacy rules in each country make this less like copying a website and more like fitting a new key for every door.

    Competes with Numan Weight Loss Programme (Numan) · Manual Weight Loss (Manual)

  • Low Testosterone· Product lineRampingLaunched in the second half of fiscal 2025, this became the fastest-growing specialty outside weight management. Management expects it to approach a $100 million yearly sales pace; testing and hormone-care rules gate that growth.

    Launched in the second half of fiscal 2025, this became the fastest-growing specialty outside weight management. Management expects it to approach a $100 million yearly sales pace; testing and hormone-care rules gate that growth.

    In plain English

    Here the sale begins with proof. A man completes lab work, a provider reviews the result, and only someone found eligible moves into treatment. The current main offer is a prescription drug called enclomiphene, priced on a prepaid plan equal to $99 a month.

    Hims earns as approved customers continue treatment and repeat the required monitoring. The company plans to add injectable and oral choices, which could serve more preferences but also makes careful testing and medical oversight more important. Labs and drug makers get paid along the way; Hims connects those steps into one service.

    Competes with Hone TRT (Hone Health) · Rex MD Testosterone (Rex MD)

  • Labs· ServiceRampingA paid health check covering more than 130 body measurements, followed by interpretation and an action plan. The bigger opportunity is not the test alone, but whether results lead eligible customers into other Hims care.

    A paid health check covering more than 130 body measurements, followed by interpretation and an action plan. The bigger opportunity is not the test alone, but whether results lead eligible customers into other Hims care.

    In plain English

    Instead of waiting for a symptom, customers can order a broad health check through Hims. A provider orders the work, Quest draws the sample at one of its locations, and Hims explains the results and suggests next steps; testing partner GRAIL supplies an optional Galleri screening test.

    Customers pay for the testing and guidance. The service can also reveal that someone may qualify for another Hims treatment, but that later purchase belongs to the other specialty. Hims bought YourBio to work toward small at-home blood samples, which could remove the trip to a collection site if it reaches scale.

    Competes with Function membership (Function Health) · Superpower membership (Superpower)

  • Peptide Therapeutics· ProductPre-revenueNothing is being sold yet. Hims may pay an unnamed manufacturing partner up to $30 million over twelve months as work clears agreed progress steps; any product launch still depends on regulators.

    Nothing is being sold yet. Hims may pay an unnamed manufacturing partner up to $30 million over twelve months as work clears agreed progress steps; any product launch still depends on regulators.

    In plain English

    This is a planned line of prescription treatments known as peptides, not a current business. Hims is building the ability to make their ingredients and finished doses. Several are targeted to launch first, while one candidate called BPC-157 can move only if regulators permit it.

    If launched, Hims would connect manufacturing, provider approval and pharmacy delivery, earning money when eligible patients receive treatment. For now the flow runs the other way: the company is investing in production and may owe its technology partner as development steps are completed. Management attention gives the project strategic weight, but there are no customers or sales to count yet.

    Competes with Hone peptide program (Hone Health) · PT-141 therapy (Lifeforce)

Named in filings, launches and programs

  • Mental HealthServiceOnline evaluation and prescription management for anxiety and depression remains available, though management has spoken about it less often.
  • Menopause SupportProduct line · RampingPrescription care for perimenopause and menopause launched in the second half of fiscal 2025; sales have not been disclosed.
  • Hims & Hers app and AI care toolsPlatform · RampingSoftware answers many nonmedical questions and reduces support work; its value shows up through service costs and customer retention, not separate sales.
  • Affiliated Medical Groups / Provider NetworkEcosystemPhysician-owned groups supplied 1,586 U.S. providers at fiscal 2025 year-end; Hims receives a fixed fee for administrative support.
  • WholesaleServiceA small $36.2 million sideline selling through established partners, which supplied more than nine-tenths of its fiscal 2025 sales.
  • Nonprescription wellness products, supplements and devicesProduct lineNonprescription products sit alongside specialty care, but Hims does not disclose their sales separately.
  • Mental HealthService

    Online evaluation and prescription management for anxiety and depression remains available, though management has spoken about it less often.

  • Menopause SupportProduct line · Ramping

    Prescription care for perimenopause and menopause launched in the second half of fiscal 2025; sales have not been disclosed.

  • Hims & Hers app and AI care toolsPlatform · Ramping

    Software answers many nonmedical questions and reduces support work; its value shows up through service costs and customer retention, not separate sales.

  • Affiliated Medical Groups / Provider NetworkEcosystem

    Physician-owned groups supplied 1,586 U.S. providers at fiscal 2025 year-end; Hims receives a fixed fee for administrative support.

  • WholesaleService

    A small $36.2 million sideline selling through established partners, which supplied more than nine-tenths of its fiscal 2025 sales.

  • Nonprescription wellness products, supplements and devicesProduct line

    Nonprescription products sit alongside specialty care, but Hims does not disclose their sales separately.